Big drug makers keeping a close eye on Neurontin lawsuit

04/19/2004 | U.S. News & World Report

The legal battle over the marketing practices surrounding the epilepsy drug Neurontin and its off-label uses has major pharmaceutical companies waiting anxiously for a decision. The suit claims Parke-Davis, now part of Pfizer, engaged in illegal off-label promotion, and a victory for the plaintiff could lead to investigations of other drug companies' practices in the off-label area and force companies to look closely at their compliance and training practices. Some say the federal government is interested in a crackdown on off-label uses to cut its costs under the new Medicare prescription drug law.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ